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Many patients with moderate-to-severe plaque psoriasis 
do not respond adequately to methotrexate monothera-
py. This pilot study, with a small patient population, was 
performed to evaluate the effectiveness and safety of eta-
nercept and methotrexate combination in patients with 
plaque psoriasis and inadequate response to methotrex-
ate. Outpatients with plaque psoriasis (Psoriasis Area 
and Severity Index ≥ 8 and/or body surface area > 10%), 
despite methotrexate treatment (≥ 3 months; ≥ 7.5 mg/
week) were randomized to either etanercept with metho­
trexate tapered and discontinued (n = 28) or etanercept 
with continuous methotrexate (n = 31). Significantly 
more patients had a Physicians’ Global Assessment of 
“clear”/”almost clear” in the combination group compa-
red with etanercept/methotrexate taper (66.7 vs. 37.0%, 
respectively; p = 0.025). Adverse events were similar for 
both groups, with no cases of tuberculosis, malignancies 
or opportunistic infections reported. Addition of etaner-
cept to methotrexate achieved significant improvement 
in psoriasis after 24 weeks. Key words: etanercept; metho­
trexate; psoriasis.
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Psoriasis is a chronic, inflammatory skin disorder, esti-
mated to affect about 2.5% of the global population and 
approximately 1.5% of people in central Europe (1, 2). 
Plaque psoriasis is the most common form, diagnosed 
in 80% of patients with psoriasis (3). About a quarter of 
those with psoriasis have moderate-to-severe disease, 
but psoriasis of almost any severity has a profound 
effect on patients’ health-related quality of life (4, 5). 
This is commonly because of psychosocial effects (e.g. 
contemplating suicide, and difficulties interacting with 
work colleagues, family and friends or finding a job), or 
difficulties in performing normal daily activities (e.g. 
using hands, walking, sleeping, standing or sitting for 
long periods, or sexual activities) (4). The definition of 
psoriasis severity includes the effect of the disease on 
patients’ quality of life, disease history, signs and symp-
toms. For example, the “rule of tens” for current severe 
psoriasis is defined as at least 10% of body surface area 
(BSA) involved, or a Psoriasis Area and Severity Index 
(PASI) score of at least 10 or a Dermatology Life Quality 
Index (DLQI) score of at least 10 (6, 7).
Although topical treatments may suffice to control 
mild psoriasis, moderate-to-severe psoriasis often requi-
res the use of phototherapy, systemic drugs, or both (1, 
8). However, current systemic therapies for moderate-
to-severe psoriasis are associated with short- and long-
term toxicity, and a concomitant high level of patient 
dissatisfaction (8, 9). There is a need for well-tolerated 
and more effective therapies for this patient group.
Methotrexate is the most commonly used systemic 
treatment for moderate-to-severe plaque psoriasis in 
Europe (9, 10), and is effective in reducing disease seve-
rity by at least 50% in the majority of patients (11, 12). 
However, methotrexate is associated with potentially 
serious toxic effects, including haematological toxicity, 
hepatotoxicity and lung disease, limiting the dose and 
duration of treatment and requiring careful monitoring 
of hepatic, renal and haematological parameters (8). 
Methotrexate also lacks effectiveness in a substantial 
proportion of patients.
Etanercept is a fully soluble, human tumour necrosis 
factor (TNF) receptor and reduces the inflammatory 
response by inhibiting interactions between TNF and 
cell-surface receptors (13, 14). Etanercept monotherapy 
has been shown to be effective in treating plaque pso-
riasis in several randomized, double-blind trials, and 
is also associated with a good safety and tolerability 
profile (15–17). Recent trials in patients with rheuma-
toid arthritis who had an inadequate response to metho-
trexate monotherapy have shown that the addition of 
etanercept produces substantial clinical improvements 
without an increase in adverse events (18–20). More-
over, a study conducted in a small number of patients 
(n = 6) with moderate-to-severe psoriasis showed that 
etanercept can allow the tapering of methotrexate dose 
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without increasing liver toxicity, infections or myelo-
suppression (21).
The objective of this study was to evaluate the ef-
fectiveness of combining etanercept with continued 
methotrexate treatment and of etanercept with metho-
trexate taper in outpatients with active plaque pso-
riasis (PASI > 8, BSA ≥ 10%), despite treatment with 
methotrexate for at least 3 months. The design of the 
study was chosen to be similar to routine practice with 
systemic therapies when treating psoriasis patients. This 
is a 24-week, randomized, open-label, parallel-group, 
multicentre pilot study.
METHoDS
Study protocol
The study protocol was approved by local ethics committees 
and was conducted in accordance with the Declaration of Hel-
sinki and its amendments. Patients giving written informed 
consent were recruited from two centres in each of the follo-
wing countries: Denmark, Finland, Norway and Sweden. The 
randomization schedule was computer generated and performed 
in randomly permuted blocks of four, with one randomization 
list per centre. As this was an open-label study, patients were 
not blinded to the treatment they were assigned.
Patients were invited to participate in this study if they were at 
least 18 years of age and had active plaque psoriasis involving 
at least 10% of their BSA and/or a minimum screening PASI 
score of 8. In addition, patients had to have been treated with 
methotrexate at a dose of at least 7.5 mg/week for 3 months 
before the study and had an inadequate response. The 3-month 
period was chosen to obtain a stable methotrexate dose, although 
the majority of the patients had been on methotrexate treatment 
for many years. The minimum level of 7.5 mg methotrexate was 
chosen in order not to exclude the few patients who had been 
treated with higher doses of methotrexate, but where it had been 
necessary to reduce dose due to gastrointestinal-symptoms, liver 
toxicity or other side-effects such as tiredness.
Sexually active women of child-bearing age were required to 
use a medically accepted form of contraception. Exclusion criteria 
included: presence of predominantly guttate, erythrodermic or 
pustular psoriasis; previous use of a TNF-inhibitor; skin condi-
tions other than psoriasis that could interfere with effectiveness 
evaluations of trial medications; use of systemic corticosteroids, 
psoralen plus ultraviolet A radiation, cyclosporine, acitretin, 
alefacept, efalizumab, tar compounds, vaccination with live 
attenuated vaccine or the presence of active severe infections in 
the 4 weeks before starting the trial; ultraviolet light B (UVB), 
topical group III or IV steroids, topical vitamin A or D or anthralin 
in the 2 weeks before starting the trial; a history of alcohol or 
drug abuse; lactation; clinically relevant diseases.
Randomization was performed at the baseline visit, and addi-
tional clinic visits were performed at 2, 4, 8, 12, 18 and 24 weeks 
to assess the effectiveness and safety of the trial medications. 
Treatments
Patients were randomized to receive 24 weeks of treatment as 
follows: (i) etanercept with methotrexate tapered and discon-
tinued during the first 4 weeks of the trial or (ii) etanercept 
combined with continued methotrexate treatment. For patients 
in both groups, etanercept was given subcutaneously, 50 mg 
twice weekly for 12 weeks, and then 25 mg twice weekly for 
the remaining 12 weeks of the study. 
Outcome measures
The primary effectiveness variable was the proportion of pa-
tients who were classified as “clear” (score of zero) or “almost 
clear” (score of one) on the Physician’s Global Assessment 
(PGA) scale at week 24. Secondary variables included the fol-
lowing: PGA “clear” or “almost clear” at 12 weeks; PGA of 
head, scalp and neck “clear” or “almost clear” at weeks 12 and 
24; time to PGA “clear” or “almost clear”; PASI improvement 
at weeks 2, 4, 8, 12, 18 and 24; PASI 50, PASI 75 and PASI 
90 responses (proportion of patients with an improvement of 
PASI of at least 50, 75 and 90% from baseline, respectively) 
at weeks 12 and 24; patients’ global assessment of psoriasis, 
itching, joint pain and tiredness (each criterion was assessed 
using a scale from 0 (good, no itching, no pain, no tiredness, 
respectively), to 5 (severe, severe itching, severe pain and very 
tired, respectively) at weeks 12 and 24; and DLQI and EuroQoL 
5D (EQ-5D) scores at weeks 12 and 24. Safety was evaluated 
by recording adverse events, vital signs, physical examinations, 
blood laboratory tests and the proportion of patients who dis-
continued due to adverse events.
Statistical analysis 
The statistical analyses were performed by PCG. SAS version 
8.02 software was used in all analyses. Results were summarized 
by visit for the full analysis set (FAS; i.e. randomized patients 
who had taken at least one dose of study medication and had 
a least one post-randomization observation). The primary ef-
fectiveness variable was analysed using a two-sided 95% con-
fidence interval (CI) for the difference between treatments for 
the proportion of patients who were "clear" or "almost clear" 
at week 24. A χ2-test of difference between treatments was 
performed. Secondary outcome measures were analysed in the 
same manner with the following exceptions. For percentage 
improvements in PASI scores, a two-sided 95% CI for the dif-
ference between treatments was calculated at each respective 
time-point. Differences between treatments were tested with 
ANCoVA with baseline values as the covariate. Time to PGA 
“clear” or “almost clear” used Kaplan–Meier estimates of time 
to “clear” or “almost clear” displayed in a graphical format and 
a corresponding log-rank test to look for any difference between 
treatments. Differences between treatments for patients’ global 
assessment of psoriasis were analysed with the extended 
Mantel-Haenszel mean score statistic using modified ridit 
score and adjusting for value at baseline. DLQI and EQ-5D 
scores were analysed by calculating a two-sided 95% CI for the 
difference between treatments, with difference between 
treatments tested using ANCoVA with baseline value as the 
covariate. Safety variables were analysed using descriptive 
statistics, but no formal statistical comparisons were made. 
A patient number of 60 for this pilot study was estimated for 
practical reasons rather than for statistical comparison between 
treatment groups, as data concerning the treatment of patients 
with psoriasis who fail methotrexate therapy are sparse. Thus, 
this study was designed to gather information about etanercept, 
with or without concurrent methotrexate, for this difficult-to-
treat group of patients with plaque psoriasis. Sixty patients 
allows for a precision of ± 0.13 percentage points for the 95% 
CIs with respect to the primary effectiveness variable.
ResulTs
Participant flow and baseline results
Fig. 1 shows the flow of patients through the study. 
Sixty patients were enrolled, of whom 59 were ran-
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domized to one of two treatments: etanercept with 
methotrexate taper (n = 28) or etanercept combined 
with continued methotrexate treatment (n = 31), with 
one patient withdrawn due to a positive tuberculosis 
test during screening. All 59 patients were included in 
the safety analysis and effectiveness analysis (FAS). All 
results presented here are for the FAS data-set. 
Five patients (17.9%) withdrew from the etanercept/
methotrexate taper group and 3 (9.7%) from the com-
bination therapy group during the course of the trial. 
For the etanercept/methotrexate taper group, 3 of these 
withdrawals were because of serious adverse events 
and 2 were because of lack of effectiveness. For the 
combination therapy group, one patient each withdrew 
because of lack of effectiveness, lack of compliance and 
the decision of the principal investigator. 
Baseline demographics and baseline effectiveness 
variables are presented in Table I. The methotrexate dose 
received prior to initiation of the study was similar in 
both the etanercept/methotrexate taper and combination 
groups (14.0 (range 7.5–25.0) and 13.4 (range 7.5–25.0) 
mg/week, respectively). The only significant difference 
between treatment groups regarding baseline characte-
ristics was that a larger proportion of women were in 
the etanercept/methotrexate taper group compared with 
the combination treatment group (p = 0.046). 
Effectiveness
Improvements in psoriasis symptoms, as measured by 
the primary and secondary effectiveness variables, were 
observed in both treatment groups over the course of the 
study. The primary effectiveness variable (proportion of 
patients judged as “clear” or “almost clear” according 
to the PGA at week 24) was superior for etanercept 
combined with continued methotrexate treatment 
compared with etanercept/methotrexate taper (66.7 
vs. 37.0%, respectively; p = 0.025; adjusted for gender 
p = 0.027; Fig. 2). There were marked improvements in 
PGA scores in the combination treatment group, with 
86.6% of patients achieving scores of 0–2 at week 24 
compared with 74.0% for the etanercept/methotrexate 
taper group. 
Both treatment groups demonstrated an improve-
ment in PAsi score from baseline. Results showing the 
proportion of patients with a PASI improvement of at 
Fig. 1. Patient flowchart.
Table I. Characteristics at baseline of patients randomized to receive etanercept with methotrexate tapered over the first 4 weeks or 
etanercept combined with continued methotrexate treatment
Characteristic or effectiveness measure
Treatment
Total
(n = 59)
Etanercept/methotrexate
taper (n = 28)
Etanercept with continued 
methotrexate (n = 31)
Mean age, years 47.3 48.7 48.1
Mean body weight, kg 89.9 83.7 86.6
Mean body mass index, kg/m2 30.1 27.6 28.8
Mean body surface area involvement, % 24.9 26.2 25.6
Mean psoriasis duration, years 21.0 23.0 22.0
Race, n (%) of patients
  Caucasian
  Asian/South American
27 (96.4)
  1 (3.6)
30 (96.8)
  1 (3.2)
57 (96.6)
  2 (3.4)
Gender, n (%) of patients
  Males
  Femalesa
17 (60.7)
11 (39.3)
26 (83.9)
  5 (16.1)
43 (72.9)
16 (27.1)
PGA 2.9 3.2 3.0
PGA, assessment of head, scalp and neck 2.3 2.3 2.3
PASI 16.8 17.4 17.1
DLQI, total score 11.2 9.0 10.1
Methotrexate dose, mg/week 14.0 13.4 13.7
ap = 0.046 for percentage of females given etanercept/methotrexate taper vs. those given etanercept combined with continued methotrexate treatment.
DLQI: Dermatology Life Quality Index; PASI: Psoriasis Area and Severity Index; PGA: Physicians’ Global Assessment of psoriasis.
Acta Derm Venereol 88
498 C. Zachariae et al.
least 50, 75 and 90% from baseline are shown in Fig. 
2. Achievement of PASI 75 over time is shown in Fig. 
3. Results for PAsi 75 at both 12 weeks and 24 weeks 
were significantly better for combination treatment than 
etanercept/methotrexate taper even when adjusted for 
gender differences. Results for mean percentage impro-
vements in PASI scores from baseline show that by 18 
weeks of treatment, combination therapy was signifi-
cantly superior to etanercept/methotrexate taper (79.9 
vs. 62.8, respectively; p = 0.023; adjusted for gender 
p = 0.019), an effect that was maintained until the end 
of the study (76.4 vs. 51.3%, respectively; p = 0.019; 
adjusted for gender p = 0.021).
Patients’ global assessment of psoriasis showed sig-
nificant improvement at week 12 (p = 0.011) and week 
24 (p = 0.012) for etanercept combined with continued 
methotrexate treatment vs. etanercept/methotrexate 
taper. PGA of head, scalp and neck “clear” or “almost 
clear” after 12 weeks was also significantly better for 
combination than etanercept/methotrexate taper treat-
ments (93.1 vs. 65.4%, respectively; p = 0.010; adjusted 
for gender p = 0.023), but by week 24 this difference 
was no longer significant (86.7 vs. 66.7%, respectively; 
p = 0.072, adjusted for gender, p = 0.155). 
DLQI scores indicated an improvement in quality 
of life over the study period for both groups. At week 
24, there were greater reductions in DLQI from base-
line for patients in the combination treatment group 
than those in the etanercept/methotrexate taper group 
(improvements of 74 and 48%, respectively; p = 0.076; 
adjusted for gender p = 0.12). Likewise, EQ-5D scores 
were improved in both groups at 24 weeks although 
the difference between the treatment groups did not 
reach significance (p = 0.217). The actual increases in 
EQ-5D scores of 0.19 and 0.12 for the combination and 
etanercept/methotrexate taper groups, respectively, are 
considered a clinically meaningful change in quality of 
life (utility), where a minimally important difference 
is 0.07 (22).
Safety and tolerability
There was very little difference between treatment 
groups for the number of patients experiencing adverse 
events or the total number of adverse events reported 
(Table II). A total of 101 adverse events were reported: 
51 in the etanercept/methotrexate taper group and 50 
in the combination treatment group. The most common 
organ system class affected by adverse events was 
infections, where 7 (25.0%) and 12 (38.7%) adverse 
events were reported for the etanercept/methotrexate 
taper and combination groups, respectively. This was 
followed by general disorders and administration site 
conditions with 8 (28.6%) and 5 (16.1%), respecti-
vely, and skin and subcutaneous tissue disorders with 
7 (25.0%) and 5 (16.1%) events, respectively. A total 
of 7 adverse events were considered serious, 5 events 
reported in 4 patients in the etanercept/methotrexate 
taper group and 2 events reported in one patient in the 
combination group, all of which were considered to be 
related to the study medication. Three of these serious 
adverse events were infections (2 in the etanercept/
methotrexate taper group and one in the combination 
group). Pustular psoriasis, heart insufficiency and atrial 
fibrillation also occurred in the etanercept/methotrexate 
taper group and vomiting occurred in the combination 
group. Three patients discontinued due to adverse 
events in the etanercept/methotrexate taper group, but 
none in the combination treatment group. No cases of 
Fig. 2. The proportion of patients (A) classified as “clear” or “almost clear” 
on the Physician’s Global Assessment (PGA) of psoriasis scale and (B) with 
an improvement of Psoriasis Area and Severity Index (PASI) of at least 50%, 
75% and 90% from baseline, respectively, at weeks 12 and 24 (data for all 
non-missing observations are shown). 
Fig. 3. Improvements in Psoriasis Area and Severity Index (PASI) scores of at 
least 75% from baseline at all time-points assessed (data for all non-missing 
observations are shown) *p < 0.05 for the difference between study groups 
(with and without adjustment for gender).
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malignancies, opportunistic infections or tuberculosis 
were observed.
DISCUSSION
This study reports on the effectiveness of the addition 
of etanercept to methotrexate treatment in patients with 
active plaque psoriasis despite methotrexate therapy. 
Treatment beneﬁt with etanercept plus methotrexate 
was demonstrated across a wide range of measures and 
no concerns were raised relating to the tolerability of 
combination therapy. 
Improvements in psoriasis symptoms from baseline 
were observed in both treatment arms, with the com-
bination group demonstrating statistically superior 
results compared with etanercept/methotrexate taper 
in PGA “clear” or “almost clear”, mean percentage 
improvement in PASI score from baseline and PASI 
75 scores. This pilot study was conducted in a small 
patient population which may have contributed to the 
failure to reach a statistically signiﬁcant difference in 
PASI 50 and PASI 90 results despite the combination 
group demonstrating higher numerical rates of impro-
vement compared with etanercept/methotrexate taper 
at all time-points from 4 weeks. 
Quality of life also improved for both groups, with 
greater improvement observed in the combination 
treatment arm compared with etanercept/methotrexate 
taper. However, the difference between treatments did 
not achieve statistical signiﬁcance. Quality of life mea-
surements are generally considered more variable than 
clinical endpoints, which could explain the failure to 
reach a statistically signiﬁcant difference. 
The effectiveness ﬁndings are important because the 
patient population studied is notoriously difﬁcult to 
treat. Patients in this study have suffered from psoriasis 
symptoms for an average of 22 years in total and PASI 
scores upon entry into this study were well above the 
minimum entry criteria (average 17.1; range 8–42). 
Therefore these patients represent a group with severe 
psoriasis symptoms, who have responded inadequately 
to methotrexate treatment. Patients were receiving an 
average methotrexate dose of 13.7 mg per week. In 
a large number of patients the initial methotrexate 
dose had been reduced due to intolerance for different 
reasons, such as gastrointestinal complaints, tiredness 
and liver toxicity. The patient population in this study 
represent the daily situation for the clinicians in der-
matological departments, where a large number of the 
psoriasis patients with prolonged disease symptoms are 
treated with methotrexate and other systemic therapies. 
It is therefore important to consider new therapeutic 
options in patients with severe disease despite metho-
trexate treatment.
Data on PASI scores prior to methotrexate therapy 
could not be obtained for patients in this study. It is 
common for psoriasis studies to have a washout period 
of systemic therapy prior to baseline, which enables a 
“true” PASI response to the study treatment to be recor-
ded. However, this was not possible with this particular 
study design. Taking this into consideration, a “true” 
PASI response to etanercept and methotrexate combi-
nation in treatment-naïve patients would be expected to 
be higher than the PASI 75 of 70% at week 24 reported 
for this study. However, the effectiveness results for 
PGA and PASI were very favourable for patients in the 
etanercept and methotrexate combination group, sug-
gesting an additive effect for these two agents.
The additive effect observed in the present trial 
between etanercept and methotrexate is not surprising, 
Table II. Summary of adverse events
Etanercept/methotrexate taper (n = 28) Etanercept with continued methotrexate (n = 31)
Number (%) of patients
Any adverse event 21 (75.0) 19 (61.3)
Any serious adverse events 4 (14.3) 1 (3.2)
Infection, hospitalized
Pustular psoriasis in handsa
Pneumonia
Heart insufﬁciency/atrial ﬁbrillation
Vomited (blood in vomit)/respiratory infection 
1 (3.6)
1 (3.6)
1 (3.6)
1 (3.6)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
1 (3.2)
Discontinuation of study treatment due to adverse event 3 (13.0) 0 (0.0)
Number (%) of events
Total adverse events 51 50
Related to study medication 28 26
Most common adverse event by organ system class
   Infections
   General disorders and administration site conditions
   Skin and subcutaneous tissue disorders
7 (25.0)
8 (28.6)
7 (25.0)
12 (38.7)
  5 (16.1)
  5 (16.1)
Total serious adverse events 5 2
Related to study medication 5 2
aThis was not a transformation of disease.
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given that it is established practice to use rational com-
binations of treatments with different modes of action 
to treat psoriasis (1, 23). Thus, although the mechanism 
of action of methotrexate is not fully understood, it is 
thought to act as an immunosuppressant and targets 
lymphoid cell functions, whereas etanercept specifically 
targets  TNFα (1, 8, 24).  
The effectiveness of etanercept alone for moderate-
to-severe psoriasis is well documented, both over 12–24 
weeks (15–17), and over much longer periods of up to 3 
years (25, 26). Such studies reveal high response rates: 
PASI 75 was achieved in 54–59% of patients at week 
24 in three previous trials (15–17). The lower PASI 75 
response observed here in the etanercept/methotrexate 
taper group (37% of patients achieved PASI 75 at week 
24) is a consequence of multiple factors. First, as explai-
ned for the combination group, the “true” PASI respon-
ses that could be achieved with etanercept alone in treat-
ment-naïve or “washed-out” patients would be higher 
than those obtained in this study with etanercept after 
withdrawal of methotrexate. Secondly, a reduced rate of 
improvement following the withdrawal of methotrexate 
in these patients with severe disease and an inadequate 
response to prior methotrexate monotherapy. A similar 
situation was observed when one agent was withdrawn 
from combined methotrexate and cyclosporine therapy 
administered to patients with severe psoriasis (27). 
Etanercept was well tolerated in both treatment 
groups, with no new safety signals. Moreover, there 
were no cases of malignancies, opportunistic infections 
or tuberculosis in the study reported here. However, 
malignancies due to treatment would not be expected 
to appear in the time course of this study. These events 
have been observed with methotrexate, and, rarely, with 
etanercept monotherapy (8, 13). The results of this study 
are consistent with safety data from larger, long-term 
studies of combination therapy with etanercept and metho-
trexate. In a 3-year study of patients with rheumatoid 
arthritis treated with the combination of etanercept and 
methotrexate, clinical improvements were sustained 
through 3 years with no latent tolerability issues (28).
In conclusion, this study showed that patients with 
active plaque psoriasis despite methotrexate treatment 
benefited significantly from the addition of etanercept 
to their methotrexate treatment regimen with no adverse 
effect on safety. This study warrants repetition in a 
larger patient cohort and over a longer study period to 
confirm these initial observations. Nonetheless, these 
results are promising as they provide clinicians with a 
further option to address this difficult-to-treat patient 
population. Patients with psoriasis are a heterogeneous 
group and respond differently to the available therapies. 
Thus, the treatment regimen needs to be adapted to suit 
the individual’s needs taking into account disease seve-
rity, impact on quality of life, practicality of treatment 
and treatment history. 
Given the results presented here, clinicians should 
consider the addition of etanercept for patients respon-
ding inadequately to methotrexate.
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